Traders should view this as a positive catalyst for Brainsway's commercial growth, as broader payer support for NP-administered TMS could accelerate adoption in underserved areas. Monitor future quarterly revenue trends and commentary on treatment volume for validation of this expansion.
Price Chart
Executive Summary
Brainsway highlighted expanding U.S. payer coverage allowing nurse practitioners to administer its Deep TMS therapy, including a key policy update from Optum/United Behavioral Health covering 34.8 million lives. This shift is expected to broaden access to treatment by addressing clinician shortages, potentially increasing utilization of Brainsway's devices.
Key Facts
- Optum/United Behavioral Health updated its TMS clinical policy in late 2025 to allow psychiatric mental health nurse practitioners (PMHNPs) to order, supervise, and administer TMS therapy in states with full practice authority.
- The Optum policy change applies to commercial plans covering approximately 34.8 million lives.
- Other major payers, including Medicare Administrative Contractors (First Coast, National Government Services, Novitas), the U.S. Department of Veterans Affairs, and TRICARE West, have also adopted similar policies.
- Previously, TMS administration under Optum's policy was limited to psychiatrists.
- Brainsway states this trend removes structural barriers and expands access to its FDA-cleared Deep TMS treatments for depression, OCD, and smoking addiction.
Financial Impact
Potential revenue upside from increased treatment adoption due to expanded provider pool; Optum's coverage alone represents a significant portion of the U.S. commercial insurance market.
Risk Factors
- Impact may be gradual as clinics adapt to new provider models.
- Reimbursement rates and prior authorization requirements still vary by payer and could limit uptake.
- Forward-looking statements are subject to regulatory, operational, and market risks as detailed in the filing.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001171843-26-002457 |
| Document: f6k_041426.htm | 0001171843-26-002457 |
| Document: 0001171843-26-002457-index-headers.html | 0001171843-26-002457 |
| Document: 0001171843-26-002457-index.html | 0001171843-26-002457 |
| Document: 0001171843-26-002457.txt | 0001171843-26-002457 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Jun 9, 2026 16w ago | 6-K | $16.84 $15.13 | ▼ −10.15% | ▼ −14.24% | $15.13 (−10.15%) |
May 18, 2026 19w ago | 6-K | $16.84 $15.13 | ▼ −10.15% | ▼ −15.01% | $15.13 (−10.15%) |
May 13, 2026 20w ago | 6-K | $16.84 $15.13 | ▼ −10.15% | ▼ −14.59% | $15.13 (−10.15%) |
Apr 20, 2026 23w ago | 20-F | $13.55 $15.13 | ▲ +11.66% | ▲ +4.76% | $15.13 (+11.66%) |
Apr 15, 2026 24w ago | 6-K | $13.55 $15.13 | ▲ +11.66% | ▲ +3.52% | $15.13 (+11.66%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access